National Institute of Mental Health; Notice of Closed Meetings, 73781-73782 [05-23942]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 238 / Tuesday, December 13, 2005 / Notices
marketed under the tradename Gleevec.
Mitoxantrone is also used to treat
certain types of cancers and multiple
sclerosis. For all of these compounds
the FDA approved new and expanded
uses and there is intense interest in
determining whether and where each of
the compounds actually collects in the
body, and especially whether they are
taken up by the targeted tumor.
Traditional approaches to determine
drug uptake and retention have been
invasive. Advantages of using this
technology include: (1) Avoidance of
exposing patients to toxic drugs that
have no potential for benefit; (2) ability
to rapidly determine whether a given
tumor will be likely to respond to a
particular drug; and (3) the ability to
monitor the impact of various dosages,
schedules, and modulators for delivery,
in situ, at the actual tumor under
treatment conditions. Further, methods
to guide treatment of solid tumors, with
labeled taxanes, are also disclosed in the
present application.
Additional information may be found
in: Ravert et al., ‘‘Radiosynthesis of
[11C]paclitaxel,’’ J Label Compd and
Radiopharm, 2002, 45(6):471–477.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Dated: December 1, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E5–7249 Filed 12–12–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes Of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
ACTION:
Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
VerDate Aug<31>2005
00:22 Dec 13, 2005
Jkt 208001
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
Quantitative Assay of the Angiogenic
and Antiangiogenic Activity of a Test
Molecule
Steven K. Libutti (NCI).
U.S. Patent Application No. 11/014,472
filed 16 Dec 2004 (HHS Reference No.
E–152–2002/1–US–01).
Licensing Contact: Mojdeh Bahar; 301–
435–2950; baharm@mail.nih.gov.
The invention provides a method of
measuring the angiogenic or
antiangiogenic activity of a test
molecule. The method comprises
obtaining an embryonated fowl egg,
creating a window in the shell of the
fowl egg, such that the CAM membrane
is exposed, providing to a test region of
interest on the CAM a substrate,
administering to a vessel located in the
CAM a test molecule, administering to
a vessel located in the CAM a
fluorescent-labeled particle, such that
the fluorescent-labeled particle travels
through each vessel contained in the
test region of interest, removing the
substrate and the test region of interest
from the fowl egg, capturing a threedimensional image of the test region of
interest, wherein the three-dimensional
image comprises a plurality of pixels,
such that a fluorescent vascular density
(FVD) value can be assigned to the test
region of interest, and comparing the
FVD value of the test region of interest
with the FVD value of a control region
of interest that was prepared in the same
manner as the test region of interest but
without the administration of a test
molecule, such that the angiogenic or
antiangiogenic activity of the test
molecule is measured. A lower FVD
value of the test region of interest as
compared to the FVD value of the
control region of interest is indicative of
the test molecule being useful as an
inhibitor of angiogenesis. Conversely, a
higher FVD value of the test region of
interest as compared to the FVD value
of the control region of interest is
indicative of the test molecule being
useful as a stimulator of angiogenesis.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
73781
Autotaxin: Motility Simulating Protein
Useful in Cancer Diagnosis and
Therapy
Mary Stracke, Lance Liotta, Elliot
Schiffman, Jerry Krutzch, and Jun
Murata (NCI).
U.S. Patent Application filed 16 Feb
2005 (HHS Reference No. E–142–
1990–2–US–05).
Licensing Contact: Mojdeh Bahar; 301–
435–2950; baharm@mail.nih.gov.
Cell motility plays an important role
in embryonic events, adult tissue
remodeling, wound healing and
metastasis of tumor cells. Some tumor
cells produce proteins termed
‘‘autocrine motility factors’’ that
stimulate motility in tumor cells. This
invention describes a novel tumor
protein called Autotaxin (‘‘ATX’’) that
stimulates both random and directed
migration of human A2058 melanoma
cells. ATX is a member of the
nucleotide phosphodiesterase and
pyrophosphatase (NPP) family of
proteins but is the only member of the
family that stimulates motility. It is also
the only member shown to possess
lysophospholipase D activity.
This invention can provide a
functional marker that can directly
estimate the invasive potential of a
particular human cancer. One could
also use this invention as an assay for
a particular secreted marker in body
fluids, or in tissues. Other uses include
the detection, diagnosis, and treatment
of human malignancies, and other
inflammatory, fibrotic, infectious and
healing disorders.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Dated: December 1, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E5–7250 Filed 12–12–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
E:\FR\FM\13DEN1.SGM
13DEN1
73782
Federal Register / Vol. 70, No. 238 / Tuesday, December 13, 2005 / Notices
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel,
Molecular Libraries Screening Centers
Network (MLSCN).
Date: December 9, 2005.
Time: 8 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Grand Hyatt Washington, 1000 H
Street, NW., Washington, DC 20001.
Contact Person: Yong Yao, PhD, Scientific
Review Administrator, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6149A, MSC
9606, Bethesda, MD 20892–9606, 301–443–
6102, yyao@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel,
Rapid Assessment Post-Impact of Disaster.
Date: December 21, 2005.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Christopher S. Sarampote,
PhD, Scientific Review Administrator,
Division of Extramural Activities, National
Institute of Mental Health, NIH,
Neuroscience Center, 6001 Executive Blvd.,
Room 6148, MSC 9608, Bethesda, MD 20892–
9608, 301–443–1959,
csarampo@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281 Scientist Development Award,
Scientist Development Award for Clinicians,
and Research Scientist Award; 93.282,
Mental Health National Research Service
Awards for Research Training, National
Institutes of Health, HHS)
Dated: December 1, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–23942 Filed 12–12–05; 8:45 am]
BILLING CODE 4140–01–M
VerDate Aug<31>2005
00:22 Dec 13, 2005
Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Antibiotic
Biosynthesis Program Project.
Date: December 12, 2005.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Fairmont Washington, 2401 M
Street, NW., Washington, DC .20037.
Contact Person: Noni Byrnes, PhD,
Scientific Review Administrator, Center For
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4180,
MSC 7806, Bethesda, MD 20892, (301) 435–
1217, byrnesn@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, ZRG1 BCMB
K (90) S Prions and Tau Filaments.
Date: December 20, 2005.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Arnold Revzin, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4184,
MSC 7824, Bethesda, MD 20892, (301) 435–
1153, revzina@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Fungal
Therapeutics.
Date: December 20, 2005.
Time: 3:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Alexander D. Politis, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3210,
MSC 7808, Bethesda, MD 20892, (301) 435–
1150, politisa@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Clinical
Parasitology.
Date: December 21, 2005.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Alexander D. Politis, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3210,
MSC 7808, Bethesda, MD 20892, (301) 435–
1150, politisa@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, High-end
S10s.
Date: January 26, 2006.
Time: 8:30 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Ave., NW., Washington, DC 20037.
Contact Person: Alexandra M. Ainsztein,
PhD, Scientific Review Administrator, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5144,
MSC 7840, Bethesda, MD 20892, 301–451–
3848, ainsztea@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group, Auditory System
Study Section.
Date: January 31–February 1, 2006.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Wyndham City Center Hotel, 1143
New Hampshire Ave., NW., Washington, DC
20037.
Contact Person: Edwin C. Clayton, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5095C,
MSC 7844, Bethesda, MD 20892, (301) 402–
1304, claytone@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
E:\FR\FM\13DEN1.SGM
13DEN1
]]>Agencies
[Federal Register Volume 70, Number 238 (Tuesday, December 13, 2005)]
[Notices]
[Pages 73781-73782]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-23942]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
[[Page 73782]]
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Mental Health Special
Emphasis Panel, Molecular Libraries Screening Centers Network
(MLSCN).
Date: December 9, 2005.
Time: 8 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: Grand Hyatt Washington, 1000 H Street, NW., Washington,
DC 20001.
Contact Person: Yong Yao, PhD, Scientific Review Administrator,
Division of Extramural Activities, National Institute of Mental
Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6149A,
MSC 9606, Bethesda, MD 20892-9606, 301-443-6102, yyao@mail.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Mental Health Special
Emphasis Panel, Rapid Assessment Post-Impact of Disaster.
Date: December 21, 2005.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Christopher S. Sarampote, PhD, Scientific Review
Administrator, Division of Extramural Activities, National Institute
of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd.,
Room 6148, MSC 9608, Bethesda, MD 20892-9608, 301-443-1959,
csarampo@mail.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.242,
Mental Health Research Grants; 93.281 Scientist Development Award,
Scientist Development Award for Clinicians, and Research Scientist
Award; 93.282, Mental Health National Research Service Awards for
Research Training, National Institutes of Health, HHS)
Dated: December 1, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-23942 Filed 12-12-05; 8:45 am]
BILLING CODE 4140-01-M
